Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) previous close was $11.47 while the outstanding shares total 160.97M. The firm has a beta of 1.37, a 12-month trailing P/E ratio of 13.24. IRWD’s shares traded higher over the last trading session, gaining 2.18% on 06/18/21. The shares fell to a low of $11.37 before closing at $11.72. Intraday shares traded counted 3.55 million, which was -106.59% lower than its 30-day average trading volume of 1.72M. The stock’s Relative Strength Index (RSI) is 53.29, with weekly volatility at 3.70% and ATR at 0.37. The IRWD stock’s 52-week price range has touched low of $8.63 and a $12.62 high.
Investors have identified the Drug Manufacturers – Specialty & Generic company Ironwood Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $1.86 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Ironwood Pharmaceuticals Inc. (IRWD) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 538.25 million total, with 23.6 million as their total liabilities.
IRWD were able to record 73.69 million as free cash flow during the 08/05/2021 quarter of the year, this saw their quarterly net cash flow reduce by 75.91 million. In cash movements, the company had a total of 73.69 million as operating cash flow.
Potential earnings growth for Ironwood Pharmaceuticals Inc. (IRWD)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/05/2021 quarter of the year, Ironwood Pharmaceuticals Inc. recorded a total of 88.84 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 10.02% coming in sequential stages and their sales for the 08/05/2021 quarter reducing by -31.33%.
Having a look at the company’s valuation, the company is expected to record 1.18 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on IRWD sounds very interesting.
Is the stock of IRWD attractive?
In related news, Director, Currie Mark G sold 23,571 shares of the company’s stock in a transaction that recorded on Jun 14. The sale was performed at an average price of 11.59, for a total value of 273,188. As the sale deal closes, the President and Interim CEO, MCCOURT Thomas A now sold 1,716 shares of the company’s stock, valued at 21,021. Also, CMO, SVP & Head of Drug Devt., Shetzline Michael sold 2,077 shares of the company’s stock in a deal that was recorded on May 24. The shares were price at an average price of 12.25 per share, with a total market value of 25,443. Following this completion of acquisition, the SVP, Chief Operating Officer, Rickard Jason now holds 516 shares of the company’s stock, valued at 6,321. In the last 6 months, insiders have changed their ownership in shares of company stock by 2.30%.
1 out of 5 analysts covering the stock have rated it a Buy, while 4 have maintained a Hold recommendation on Ironwood Pharmaceuticals Inc.. 0 analysts has assigned a Sell rating on the IRWD stock. The 12-month mean consensus price target for the company’s shares has been set at $12.67.